Increase in repulsive guidance molecule-a (RGMa) in lacunar and cortical stroke patients is related to the severity of the insult.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
01 12 2022
Historique:
received: 25 05 2022
accepted: 16 11 2022
entrez: 1 12 2022
pubmed: 2 12 2022
medline: 6 12 2022
Statut: epublish

Résumé

Repulsive guidance molecule-a (RGMa) inhibits angiogenesis and increases inflammation. Animal models of cerebral ischemia have shown that an increased expression of RGMa leads to larger infarction and its inhibition attenuates effects of ischemia. We report on the relationship of RGMa to stroke types and severity. This is a prospective study in patients admitted to the stroke service in Qatar. We collected the clinical determinants, including NIHSS at admission, imaging and outcome at discharge and 90-days. RGMa levels were determined by measuring mRNA levels extracted from peripheral blood mononuclear cells (PBMCs) within 24 h of onset and at 5 days. There were 90 patients (lacunar: 64, cortical: 26) and 35 age-matched controls. RGMa mRNA levels were significantly higher in the stroke patients: day 1: 1.007 ± 0.13 versus 2.152 ± 0.19 [p < 0.001] and day-5: 3.939 ± 0.36 [p < 0.0001]) and significantly higher in patients with severe stroke (NIHSS ≥ 8) compared to milder symptoms (NIHSS < 8) at day 1 (NIHSS ≥ 8: 2.563 ± 0.36; NIHSS < 8: 1.947 ± 0.2) and day 5 (NIHSS ≥ 8: 5.25 ± 0.62; NIHSS < 8: 3.259 ± 0.419). Cortical stroke patients had marginally higher RGMa mRNA levels compared to lacunar stroke at day 1 (cortical stroke: 2.621 ± 0.46 vs lacunar stroke: 1.961 ± 0.19) and day 5 (cortical stroke: 4.295 ± 0.76 vs lacunar stroke: 3.774 ± 0.39). In conclusion, there is an increase in the level of RGMa mRNA in patients with acute stroke and seen in patients with lacunar and cortical stroke. The increase in RGMa mRNA levels is related to the severity of the stroke and increases over the initial 5 days. Further studies are required to determine the effects of the increase in RGMa on stroke recovery.

Identifiants

pubmed: 36456640
doi: 10.1038/s41598-022-24481-2
pii: 10.1038/s41598-022-24481-2
pmc: PMC9715939
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

20788

Informations de copyright

© 2022. The Author(s).

Références

J Stroke Cerebrovasc Dis. 2019 Mar;28(3):619-626
pubmed: 30545720
Cell Rep. 2015 Mar 24;10(11):1887-98
pubmed: 25801027
Cell Rep. 2014 Aug 21;8(4):1146-59
pubmed: 25127134
Biomed Res Int. 2021 May 4;2021:5532116
pubmed: 33997000
Neurobiol Dis. 2021 Nov;159:105492
pubmed: 34478849
Stroke. 2015 Dec;46(12):3494-501
pubmed: 26493677
Arch Neurol. 2005 Oct;62(10):1561-8
pubmed: 16216939
Neurosci Lett. 2018 Jan 1;662:318-323
pubmed: 29061393
Trends Cell Biol. 2017 May;27(5):365-378
pubmed: 28007423
Neurochem Res. 2013 Apr;38(4):815-25
pubmed: 23389659
Nature. 2002 Sep 26;419(6905):392-5
pubmed: 12353034
Neurochem Res. 2012 Sep;37(9):1906-14
pubmed: 22692600
Nat Cell Biol. 2004 Aug;6(8):756-62
pubmed: 15258590
PLoS One. 2011;6(9):e25234
pubmed: 21957482
AJR Am J Roentgenol. 1987 Aug;149(2):351-6
pubmed: 3496763
Transl Stroke Res. 2018 Jun;9(3):274-282
pubmed: 29101611
Lancet Neurol. 2011 Oct;10(10):909-21
pubmed: 21939900
J Cell Biol. 2006 Apr 10;173(1):47-58
pubmed: 16585268
Ann Palliat Med. 2020 Sep;9(5):2933-2942
pubmed: 32819133
Cell Death Dis. 2015 May 07;6:e1744
pubmed: 25950474
Synapse. 2013 Apr;67(4):189-98
pubmed: 23184880
Brain Res Bull. 2018 Sep;142:54-62
pubmed: 29935233
Cell Death Differ. 2018 Aug;25(8):1503-1516
pubmed: 29396549
Eur Stroke J. 2016 Sep;1(3):231-241
pubmed: 31008284

Auteurs

Aijaz Parray (A)

The Neuroscience Institute, Academic Health System, Hamad Medical Corporation, 3050, Doha, Qatar.

Naveed Akhtar (N)

The Neuroscience Institute, Academic Health System, Hamad Medical Corporation, 3050, Doha, Qatar.

Ghulam Jeelani Pir (GJ)

The Neuroscience Institute, Academic Health System, Hamad Medical Corporation, 3050, Doha, Qatar.

Sajitha V Pananchikkal (SV)

The Neuroscience Institute, Academic Health System, Hamad Medical Corporation, 3050, Doha, Qatar.

Raheem Ayadathil (R)

The Neuroscience Institute, Academic Health System, Hamad Medical Corporation, 3050, Doha, Qatar.

Fayaz Ahmad Mir (FA)

Qatar Metabolic Institute, Academic Health System, Hamad Medical Corporation, 3050, Doha, Qatar.

Reny Francis (R)

The Neuroscience Institute, Academic Health System, Hamad Medical Corporation, 3050, Doha, Qatar.

Ahmed Own (A)

The Neuroscience Institute, Academic Health System, Hamad Medical Corporation, 3050, Doha, Qatar.

Ashfaq Shuaib (A)

Division of Neurology, Faculty of Medicine, University of Alberta, Edmonton, T6G 2G3, Canada. ashfaq.shuaib@ualberta.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH